Character Biosciences has raised $93m in an oversubscribed Series B funding round to expedite the progression of precision ...
The funding will help fund phase 1 and phase 2 proof-of-concept studies for lead candidates CTX203 and CTX114.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback